Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
30 hedge funds and large institutions have $2.74M invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 4 closing their positions.
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
11% more funds holding
Funds holding: 27 → 30 (+3)
3.59% more ownership
Funds ownership: 6.66% → 10.26% (+3.6%)
50% less capital invested
Capital invested by funds: $5.53M → $2.74M (-$2.79M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
+$732K |
| 2 |
Renaissance Technologies
New York
|
+$661K |
| 3 |
VF
Virtu Financial
New York
|
+$88.3K |
| 4 |
Two Sigma Advisers
New York
|
+$70.5K |
| 5 |
BlackRock
New York
|
+$60.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$179K |
| 2 |
SSWM
Smith Salley Wealth Management
Greensboro,
North Carolina
|
-$32K |
| 3 |
Morgan Stanley
New York
|
-$29.2K |
| 4 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
-$18K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.07K |
FRTX Hedge Fund Activity: Q4 2021 in Review
30 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q4 2021, worth a combined $2.74M — down 50% from $5.53M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new FRTX positions and 4 closed out — a net gain of 3 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Telemetry Investments, adding an estimated $732K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $179K sold.
- 30 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q4 2021, up from 27 in Q3 2021.
- Funds reported $2.74M of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q4 2021, down 50% quarter-over-quarter.
- 7 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of +3 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q4 2021 was Telemetry Investments, an estimated $732K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q4 2021 was GSA Capital Partners, an estimated $179K sold.
Based on aggregated 13F filings for Q4 2021.